Introduction {#s1}
============

Colorectal, gastric, and esophageal cancers are among the most commonly diagnosed cancers worldwide, as well as the more frequent causes of cancer death. Nowadays, chronic inflammation, caused by failure of the necessary self-limited acute inflammatory response, which prevents from the complete resolution of the inflammatory process, is accepted as one of the main predisposing factors to cancer ([@B8]; [@B36]). Although CRC cases are mainly "sporadic," there are several situations in which increased risk has been reported, including genetic and inflammatory disorders. These disorders include inherited mutations in the *APC* gene in FAP, those related to mismatch DNA repair in Lynch syndrome ([@B48]), or the presence of inflammatory bowel disease ([@B68]; [@B23]). Other factors contributing to chronic inflammation are bacterial infections, such as *Helicobacter pylori* (*H. pylori*) infection related to gastric cancer, or non-infectious causes of inflammation, such as esophageal reflux, the main driver of Barrett's esophagus and esophageal adenocarcinoma. In addition, other factors include reduced physical activity, an unbalanced diet like those rich in saturated fats, low fiber, red and processed meat, overweight or obesity, alcohol consumption, or smoking, which have been associated with chronic low-grade inflammation (parainflammation) and increased cancer risk too ([@B7]; [@B5]; [@B61]; [@B63]; [@B6]; [@B69]; [@B82]; [@B1]). During the inflammation onset phase, endogenous lipid mediators (LMs) like prostaglandins (PGs) and leukotrienes (LTs) are released from arachidonic acid (AA) acting as go signals for inflammation, increasing vascular permeability that enables polymorphonuclear leukocyte (PMN) infiltration into the damaged tissue, and afterwards, prostaglandins (PGE2 and PGD2) acting as stop signals mark the end of acute inflammation and the beginning of LM-class switching process by transcriptional activation of 15-lipoxygenase (15-LOX) in neutrophils and then producing the first class of endogenous specialized pro-resolving lipid mediator (SPM), AA-derived, called lipoxins (LXs), stop-and-go signals for inflammation and resolution phases ([@B66]; [@B58]; [@B71]). After LXs, other types of endogenous SPMs derived from ω3 polyunsaturated fatty acids (ω3-PUFAs) presenting as LXs, both anti-inflammatory and pro-resolving properties ([@B81]; [@B22]; [@B71]) named resolvins (Rvs), protectins (PDs), and maresins (MaRs), are produced through transcellular routes by LOX activity, orchestrating the resolution of inflammation during an active process including sequestration of pro-inflammatory cytokines, clearance of neutrophils, phagocytosis of apoptotic neutrophils, and removal of inflammatory debris and restoring tissue ([@B74]). Classical anti-inflammatory aspirin treatment, apart from inhibiting PG biosynthesis, can also generate epimeric-aspirin-triggered LXs or Rvs from PUFAs (ATL/AT-Rv) with the same protective actions and longer bioactivities ([@B31]; [@B73]; [@B72]). SPMs exert potent local bioactions and afterwards are rapidly inactivated, presenting short half-lives. For this reason, the elucidation of their chemical structures has provided a model to be used for designing mimetics analogs with reinforced stability, effectiveness, half-life, and an appropriate bioavailability, to be used as pharmacologic molecules to rescue resolution in inflammatory diseases ([@B73]). Cancer prevention programs have already been implemented in most countries, but chemoprevention agents should be considered to be used alone or in combination with other treatments to improve resolution of inflammation and prevent cancer development, since once the cancer is present, actual treatments are associated with serious adverse effects and are not effective enough in advanced tumors.

SPMs in the Resolution of Inflammatory Bowel Disease. Lesson Learned from IBD Animal Models {#s2}
===========================================================================================

Inflammatory bowel disease (IBD) is a chronic disease of the gastrointestinal tract presenting two major forms, ulcerative colitis (UC) and Crohn's disease (CD). UC is a relapsing non-transmural inflammatory condition that affects only the colon ([@B9]), whereas CD runs with relapsing transmural injuries in several parts of the gastrointestinal tract from the mouth to the anus mainly due to a dysregulated immune response to host intestinal microbiota ([@B83]). These disorders are associated with epithelial damage, leukocyte infiltration into the intestinal wall, and AA-cascade activation, increasing CRC risk. Increased risk has been described for bigger extension of inflammation, earlier onset, and longer time from diagnosis ([@B24]; [@B32]; [@B57]; [@B30]; [@B47]).The most frequently used IBD models are those generated by induction with 2,4,6-trinitrobenzenesulphonic acid (TNBS) and dextran sodium sulfate (DSS) to resemble CD and UC, respectively ([@B56]; [@B11]).

Endogenous lipoxins, the only AA-derived SPMs ([@B18]), are generated by LOX activity and act as antagonists of pro-inflammatory LTs. Oral administration of ATL analogs reduced weight loss and mortality in DSS and TNBS models and decreased colon injury, colon wall thickening, mucosal PMN infiltration, and mRNA and/or protein expression of pro-inflammatory mediators such as inducible nitric oxide synthase (iNOS), COX-2, macrophage inflammatory protein 2 (MIP-2), tumor necrosis factor-alpha (TNFα), interleukin-2 (IL-2), and IFNγ in TNBS model ([@B31]; [@B29]) ([**Table 1**](#T1){ref-type="table"}).

###### 

*In vivo* actions of synthetic pro-resolving lipid mediators (SPMs), ATL analogs and omega-3 acids in disease models.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Disease model                            Actions                                                                                                                                                                                                                                                                                                                                                                                                                         Mediator                                     References
  ---------------------------------------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------- ------------
  DSS colitis                              Reduces body weight lossImproves survival                                                                                                                                                                                                                                                                                                                                                                                       15-Epi-16-parafluoro-LXA4\                   [@B31]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                           (ATL analog)                                 

  TNBS colitis                             Reduces body weight lossImproves survivalReduces colon injuryReduces mucosal inflammationReduces PMN infiltrationReduces mRNA levels: iNOS, COX-2, MIP-2Decreases protein levels: TNFα, IL-2, IFNγ                                                                                                                                                                                                                              ZK-192\                                      [@B29]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                           (ATL analog)                                 

  TNBS colitis\                            Reduces body weight lossImproves survivalReduces colon injuryReduces PMN infiltrationReduces mRNA levels: iNOS, COX-2, IL-12 p40, TNFα                                                                                                                                                                                                                                                                                          Synthetic RvE1                               [@B4]

  DSS colitis                              Reduces body weight lossReduces colon shorteningProtects the epithelium and crypt architectureImproves disease activity indexInduces colonic ALPI mRNA expressionReduces proinflammatory IL-1β and murine KC (IL-8 human homolog)                                                                                                                                                                                               Synthetic RvE1                               [@B13]

  DSS colitis                              Reduces body weight lossReduces colon injuryImproves disease activity indexReduces PMN infiltrationReduces NF-κB activityReduces mRNA expression of TNFα, IL-1β, and IL-6                                                                                                                                                                                                                                                       Synthetic RvE1                               [@B40]

  DSS colitis\                             Reduces body weight lossImproves disease activity indexReduces colonic tissue damageReduces PMN infiltrationReduces colonic protein levels of mediators of inflammatory cell recruitment TNFα, IL-1β, MIP-2, and CXCL1/KCReduces NF-κB activity and mRNA expressionReduces mRNA expression adhesion molecules VCAM-1, ICAM-1, and LFA-1Potency AT-RvD1 \> 17R-HDHA or RvD2                                                      Synthetic\                                   [@B10]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                           AT-RvD1\                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                           17R-HDHA\                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                           RvD2                                         

  TNBS colitis\                            Reduces body weight lossImproves disease activity indexReduces colonic tissue damageReduces PMN infiltration                                                                                                                                                                                                                                                                                                                    Synthetic\                                   [@B10]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                           AT-RvD1\                                     
                                                                                                                                                                                                                                                                                                                                                                                                                                                                           17R-HDHA\                                    
                                                                                                                                                                                                                                                                                                                                                                                                                                                                           RvD2                                         

  DSS colitis\                             Reduces body weight lossReduces colon shorteningImproves disease activity indexReduces PMN infiltrationReduces colonic tissue damageReduces NF-kB activityDecreases ICAM-1 mRNA expressionReduces IL-1β, TNFα, IL-6, and IFNγ in the acute colitisReduces IL-1β, IL-6 in chronic colitis                                                                                                                                        Synthetic\                                   [@B51]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                           MaR1                                         

  TNBS colitis\                            Reduces body weight lossImproves disease activity indexReduces colonic tissue damageReduces PMN infiltration                                                                                                                                                                                                                                                                                                                    Synthetic\                                   [@B51]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                           MaR1                                         

  DSS colitis                              Reduces colon shorteningReduces colonic tissue damageReduces colon wall thicknessReduces pro-inflammatory TNFα, IL-1β, IL-6Reduces PMN infiltration                                                                                                                                                                                                                                                                             PD1n-3 DPA                                   [@B33]

  DSS colitis                              Reduces colon shorteningReduces colonic tissue damageReduces partially IL-1βReduces PMN infiltration                                                                                                                                                                                                                                                                                                                            RvD5n-3 DPA                                  [@B33]

  DSS colitis                              Reduces body weight lossReduces colonic tissue damageImproves disease activity indexReduces PMN infiltrationPotency 17-HDHA \< 17-HDPAn-6, 10,17-HDPAn-6                                                                                                                                                                                                                                                                        Synthetics:\                                 [@B17]
                                                                                                                                                                                                                                                                                                                                                                                                                                                                           17-HDPAn-6,\                                 
                                                                                                                                                                                                                                                                                                                                                                                                                                                                           10,17-HDPAn-6,\                              
                                                                                                                                                                                                                                                                                                                                                                                                                                                                           17-HDHA                                      

  APC^Min/+^ FAP model                     Reduces weight lossReduces the number of tumorsReduces the size of tumorsIncreases tissue switch from AA to EPAReduces tissue prostaglandin levels of PGE2 and 6- keto-PGF1                                                                                                                                                                                                                                                     EPA ethyl ester                              [@B37]

  APC^Min/+^ FAP model                     Reduces weight lossReduces lipid peroxidationHigh reduction in polyp numberReduces polyp load and sizeIncreases tissue switch from AA to EPAReduces COX-2 expressionReduces β-catenin nuclear translocationReduces proliferationIncreases apoptosis                                                                                                                                                                             EPA free fatty acid                          [@B28]

  NMU-colorectal model                     Reduces tumor incidenceIncreases antioxidative enzyme activities of SOD and GPxReduces lipid peroxidation                                                                                                                                                                                                                                                                                                                       Fish oil                                     [@B44]

  DSS colitis                              Increases body weight lossIncreases colon shorteningEnhances inflammationExacerbates colitisDecreases of adiponectin expression                                                                                                                                                                                                                                                                                                 Fish oil                                     [@B52]

  DSS colitis                              Reduces body weight lossReduces colon shorteningDownregulates pro-inflammatory TNFα, COX-2, mPGES, TXASUpregulates anti-inflammatory PGDSRestores the architecture of the colon epitheliumReduces inflammatory cell infiltrationReduces levels of LPO, protein carbonyl and ROSIncreases antioxidant activities of GPx, GST and GR                                                                                              Fish oil                                     [@B75]

  DSS colitis                              Reduces colon shorteningReduces disease severityReduces tissue levels of pro-inflammatory TNFα, IL-1β, and IL-6Decreases PMN infiltrationReduces NF-kB activityDecreases expression of COX-2 in colon                                                                                                                                                                                                                           EPA monoglyceride                            [@B55]

  DSS colitis\                             Reduces body weight lossReduces colon shorteningReduces colon damageReduces PMN infiltrationProduces RvE1, RvD3, NPD1, PD1, 17HDHA and 14-HDHA in colonReduces NF-kB activityDecreases mRNA level of TNFα, iNOS, IL-1βIncreases mRNA level of mucoprotective factors Tollip and TFF3                                                                                                                                            Endogenous conversion of ω6- into ω3-PUFAs   [@B38]
  Fat-1 mouse                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  CAC model\                               Reduces weight lossReduces colon shorteningDecreases inflammation severity and mucosal thicknessReduces tumor incidenceReduces tumor growth rateReduces NF-kB activityIncreases TGFβ mRNA expressionReduces iNOS mRNA expression                                                                                                                                                                                                Endogenous conversion of ω6- into ω3-PUFAs   [@B60]
  Fat-1 mouse                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  CAC model\                               Reduces tumor numberIncreases apoptosisImproves inflammation and ulceration scoresDecreases ω6 PUFA-derived eicosanoids (PGE2, PGD2, PGE1 and 12-HETE)Increases ω3 PUFA-derived eicosanoid (PGE3)Decreases CD3+, CD4+ T helper, and macrophage cell numbers in colon                                                                                                                                                            Endogenous conversion of ω6- into ω3-PUFAs   [@B41]
  Fat-1 mouse                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  CAC model\                               Reduces tumor sizeReduces colon shorteningReduces distal colon tumorogenesisReduces COX-2 protein expressionRepresses NF-κB transcriptional activationReduces mucosal PGE2 levelsPreserves tumor suppressive 15-PGDH gene expressionReduces proliferationReduces β-catenin nuclear translocationIncreases apoptosisIncreases apoptotic molecules FAS and BaxReduces expressions of antiapoptotic molecules survivin and Bcl-2   Endogenous conversion of ω6- into ω3-PUFAs   [@B35]
  Fat-1 mouse                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           

  CAC model\                               Similar ω3 tissue PUFAs content and ratio of ω6/ω3 than in the fat-1 mouseDo not confirm anti-tumorigenic effects expressed above                                                                                                                                                                                                                                                                                               DHA                                          [@B35]
  C57BL/6 mouse                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                         

  CAC model\                               [At carcinogenesis initiation:]{.ul}\                                                                                                                                                                                                                                                                                                                                                                                           EPA free fatty acid                          [@B64]
  C57BL/6J mouse\                          Reduces cell proliferationReduces β-catenin nuclear translocationIncreases apoptosis\                                                                                                                                                                                                                                                                                                                                                                                        
                                           [At carcinogenesis initiation and promotion:]{.ul}\                                                                                                                                                                                                                                                                                                                                                                                                                          
                                           Reduces tumor multiplicityReduces tumor incidenceReduces tumor sizeIncreases tissue switch from AA to EPAReduces PGE2Restores the loss of Notch signalingIncreases Lactobacillus in gut microbiota                                                                                                                                                                                                                                                                           

  Reflux esophagitis model\                Reduces esophageal damageReduces inflammationReduces expression of MyD88Decreases pro-inflammatory cytokine expression IL-1, IL-8, IL-6Increases SOD expressionReduces LPO                                                                                                                                                                                                                                                      Fish oil                                     [@B89]

  *H. pylori*-associated gastric cancer\   Reduces mucosal thickeningReduces inflammatory cell infiltrationReduces gastric inflammationReduces inflammatory COX-2, IL-1βReduces inflammatory IL-6, IL-8, IFNγDecreases angiogenic growth factors VEGF, PGDFReduces atrophic gastritis and tumorogenesisDecreases gastric cancerPreserves 15-PGDH expression                                                                                                                Endogenous conversion of ω6- into ω3-PUFAs   [@B34]
  Fat-1 mouse                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                           
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

ALPI, alkaline phosphatase; ATL, aspirin-triggered lipoxins; AT-Rv, aspirin-triggered resolving; Bax, Bcl-2 associated X protein; Bcl-2, B-cell lymphoma 2; CAC, colitis-associated cancer; COX-2, cyclooxygenase 2; CXCL1/KC, keratinocyte-derived chemokine; DSS, dextran sodium sulfate; FAP, familial adenomatous polyposis; GPx, glutathione peroxidase; GR, glutathione reductase; GST, glutathione-S transferase; HDHA, hydroxy docosahexaenoic acid; HDPAn-6, hydroxy-docosahexaenoic acid; HETE, hydroxyeicosatetraenoic acid; ICAM-1, intercellular adhesion molecule 1; IFNγ, interferon gamma; IL, interleukin; iNOS, inducible nitric oxide synthase; LFA-1, lymphocyte function associated antigen-1; LPO, lipid peroxidation; LX, lipoxin; MaR, maresin; MIP-2, macrophage inflammatory protein 2; MyD88, myeloid differentiation primary response gene 88; NF-κB, nuclear factor kappa B; NMU, N-methyl-N-nitrosurea; NPD, neuroprotection; PG, prostaglandin; PGDF, platelet-derived growth factor 15-PGDH, 15-hydroxyprostaglandin dehydrogenase; PD, protectin; PMN, polymorphonuclear leukocyte; ROS, reactive oxygen species; Rv, resolving; TNBS, trinitrobenzenesulphonic acid; SOD, superoxide dismutase; TFF3, trefoil factor 3; TGFβ, transforming growth factor beta; TNFα, tumor necrosis factor-α; TX, thromboxane; VCAM1, vascular cell adhesion protein 1; VEGF, vascular endothelial growth factor.

Resolvins are endogenous LMs derived from EPA (RvE) and DHA (RvD). As LXs, synthetic RvE1 protects against IBD induction in animal models improving survival, body weight, histological scores of disease by decreasing PMN infiltration, and gene expression of TNF-α, IL-12, iNOS, and COX-2 in TNBS model ([@B4]) and by the induction of the intestinal epithelial expression of alkaline phosphatase (ALPI) and decreasing phosphorylation of NF-κB p65 Ser276 and mRNA expression of pro-inflammatory TNF-α, IL-1β, and IL-6 in DSS model ([@B13]; [@B40]). Synthetic RvD supplementation has shown to improve colitis activity index and reduce body weight loss, colonic damage, PMN infiltration, colonic cytokine levels for TNF-α, IL-1β, MIP-2, CXCL1/KC, and NF-κB phosphorylation, as well as mRNA expression of NF-κB and the adhesion molecules VCAM-1, ICAM-1, and LFA-1 in both models. AT-RvD1 showed greater potency than its precursor 17R-HDHA and RvD2 ([@B10]) ([**Table 1**](#T1){ref-type="table"}).

Endogenous MaR1 is also a DHA-derived SPM. Synthetic MaR1 has shown similar effects to resolvins in both mentioned models. The mechanism proposed in DSS model suggests the inhibition of the NF-κB pathway and reduction of PMN transmigration and pro-inflammatory mediators like IL-1β and IL-6 ([@B51]) ([**Table 1**](#T1){ref-type="table"}).

Exogenous administration of synthesized PD1~n-3DPA~ or RvD5~n-3DPA~ reduced inflammation and improved the score of disease in the DSS model too, through a mechanism that implies regulation of neutrophil--endothelial interaction and reduction of granulocyte trafficking. The impact of PD1~n-3DPA~ in pro-inflammatory cytokines (TNF-α, IL-6, and IL-1β) was bigger, and RvD5~n-3DPA~ causes only a partial decrease of IL-1β ([@B33]). Apart from those mediators, other DPA-derived metabolites like 17-HDPAn-6 and 10,17-HDPAn-6, and although in lower degree 17-HDHA, are also effective in protecting from DSS colitis ([@B17]) ([**Table 1**](#T1){ref-type="table"}).

Previously mentioned results are consistent with the protection from DSS-induced colitis found in a mice model that overexpresses the C. elegans fat-1 gene that transforms endogenous ω6 into ω3-PUFAs, resulting in elevated tissue levels of ω3-PUFAs and increased levels of RvE1, RvD3, and PD1/NPD1 ([@B38]) ([**Table 1**](#T1){ref-type="table"}).

In conclusion, exogenous administration of AT analogs and synthetic SPMs has proved effective in improving disease and inflammatory outcomes in most frequently used IBD animal models. Current IBD therapies, based on decreasing signs and symptoms, do not eliminate the disease, cause frequent side effects, are expensive and inefficient in many patients, and cause immunosuppression, like anti-TNFα drugs. Previous results suggest that exogenous administration of stable SMPs derivates might be an innovative and more secure therapeutic approach to control intestinal inflammation, preventing CRC development.

Omega-3 PUFA Supplementation and Development of Colorectal Cancer and Related Diseases {#s3}
======================================================================================

The possible beneficial effects of ω3-PUFAs in CRC incidence was firstly suggested in 1997 in West Coast fishermen ([@B70]). Two years later, it was pointed out that several of the known risk factors for some cancers, including colon cancer, may be reduced by dietary ω3-PUFAs supplementation and encouraged the implementation of clinical chemoprevention trials ([@B67]).

Although a positive effect of ω3-PUFAs supplementation has been reported in some animal models, controversial results have been obtained in DSS and AOM models. EPA supplementation in the APC^Min/+^ mouse model of FAP reported a reduction in the number and size of tumors and improvements on weight, related to COX-2 inhibition, reductions in β-catenin nuclear translocation, and proliferation and increased apoptosis ([@B37]; [@B28]). Later, protective mechanisms based on upregulation of superoxide dismutase (SOD) and glutathione peroxidase enzymes, reductions on lipid peroxidation (LPO), and downregulated activity of pro-angiogenic genes were also proposed in N-methyl-N-nitrosurea CRC rat model and human colon carcinoma grown in nude mice ([@B43]; [@B44]). However, previous studies in DSS model have yielded contradictory results when supplemented with fish oil rich in ω3-PUFAs or EPA, showing exacerbation of colitis ([@B52]) or, by contrast, improvement of colitis scores and inflammatory eicosanoids profile, reductions on LPO, ROS levels and PMN infiltration, and increases of antioxidant enzymes ([@B55]; [@B75]). More evidence on contradictory results comes from the mouse model of colitis-associated cancer (CAC) generated by a single pretreatment with azoxymethane (AOM) and posterior ingestion of DSS. AOM/DSS-induced Fat-1 mouse model showed reduced tumor incidence, multiplicity, and size, accompanied by reduction of NF-kB activity, iNOS and COX-2 expression, β-catenin nuclear translocation, overexpression of the anti-proliferative transforming growth factor beta (TGF-β) in colon tissue, reduction of AA-derived eicosanoids, and increased apoptosis, whereas similar ω3-PUFAs content obtained by DHA supplementation in C57BL/6-AOM/DSS model fails to confirm these results ([@B60]; [@B41]; [@B35]). EPA-protective effects have been also described in non-Fat-1 AOM/DSS model related to restoration of Notch signalling and improvement of Lactobacillus gut microbiota ([@B64]) ([**Table 1**](#T1){ref-type="table"} and [**Figure 1**](#f1){ref-type="fig"}).

![Fish oil or ω3 polyunsaturated fatty acids (ω3-PUFAs) supplementation actions on gastrointestinal diseases. **(A)** Results found in animal models. **(B)** Results in human diseases.](fphar-10-00852-g001){#f1}

EPA-supplemented long-standing UC patients in stable clinical remission and active inflammation improve endoscopic and histologic scores, intestinal epithelial cell differentiation and turnover, and module gut microbiota composition ([@B65]), whereas some controversial results have been found between ω3-PUFAs and risk of CRC in prospective studies evaluating fish intake. A meta-analysis of 22 prospective cohorts and 19 case--control studies found in 2012 an overall 12% CRC risk reduction, being more pronounced for rectal cancer ([@B85]). In 2014, another meta-analysis including 60,627 individuals from prospective and case--control studies showed an opposite association between ω3-PUFAs tissue levels, especially EPA and DHA, and CRC risk ([@B87]). A study including 68,109 Washington residents found dependence of sex and anatomic subsite, with reduced risk by fish oil supplementation only in men and in colon cancer but not in rectal cancer ([@B42]). A later meta-analysis of 14 prospective studies in 2015, including 8,775 patients, found no overall association between ω3-PUFAs intake and CRC risk, in spite of observing a tendency to reduced risk in proximal region and increase in distal location of the colon ([@B15]). Although controversial results have been found between PUFAs intake and risk of CRC in prospective studies evaluating fish intake, supplementation with fish oil rich in ω3-PUFAs has shown to reduce cell proliferation in rectal mucosa of patients with sporadic CR adenomas ([@B2]; [@B3]) and/or to increased mucosal apoptosis ([@B16]; [@B21]). Probably the best evidence of ω3 supplementation comes from a randomized trial in FAP that found a significant reduction of adenomas incidence ([@B84]). The seAFOod Polyp Prevention trial has just concluded that after a year of treatment with EPA and aspirin, the risk of having at least one adenoma is not reduced, but both agents show chemopreventive activity on colorectal adenoma total burden, being EPA more effective in the left colorectum conventional adenomas and aspirin in the right colon, particularly for serrated, but also for conventional, adenomas ([@B39]) ([**Figure 1**](#f1){ref-type="fig"}).

In relation with surgery, ω3-supplementation during 7 days prior to or after CRC resection reported beneficial effects meanly interfering with inflammatory and immune responses ([@B46]; [@B78]). Finally, beneficial effects of EPA supplementation have also been found in patients undergoing liver resection for CRC liver metastases, showing reduced vascularity and increased overall survival during the first 18 months after resection, although without changes in recurrence rate ([@B19]) ([**Figure 1**](#f1){ref-type="fig"}).

As colon cancer is particularly resistant to current chemotherapeutic drugs, the role of ω3-PUFAs supplementation as part of an adjuvant therapeutic strategy in colon cancer treatment was soon proposed in order to check their influence in drug toxicity and selectivity. In this way, DHA revealed to be able to selectively target nucleoside analogue arabinosylcytosine (araC) toxicity toward colonic tumor cells without affecting the normal cells *in vitro* ([@B14]). Similar results were found in rats bearing Ward colon tumor under a cyclical regimen of CPT-11/5-fluorouracil (5-FU) where supplementation with fish oil inhibited tumor growth by raising its chemo-sensitivity and thus decreasing body weight loss, anorexia, and muscle wasting ([@B86]). Another study has proved the influence of EPA supplementation on the radio-sensitivity of colon adenocarcinoma cells HT-29 by increasing the extent of the LPO caused by radiation ([@B49]). CRC patients under chemotherapy enrolled in a prospective randomized fish oil supplementation and placebo-controlled study showed reduced CRP/albumin ratio, without changes in inflammatory cytokine profile, suggesting a reduction in the rate of development inflammatory and nutritional complications, and limiting the weight loss, suggesting that supplementation with these compounds is advisable during CRC treatment ([@B54]) ([**Figure 1**](#f1){ref-type="fig"}).

SPMs in Colorectal Cancer and Related Diseases {#s4}
==============================================

SPMs production in the gut is crucial for maintaining homeostasis, and a failure of colonic mucosa to produce adequate anti-inflammatory LMs can explain the persistent colonic inflammation in UC. Colon biopsies have shown important reductions or no detectable production of LXA4 and increased proinflammatory LTB4, PGE2, and TXB2 in IBD patients, probably due to decreased 15-LOX-2 enzyme expression, despite an apparent up-regulation of the resolving and protecting pathways from the ω-3 DPA metabolome. Innovative therapies based on SPMs DPA-derived or aspirin use in order to maintain the capacity to synthesize colonic 15-epi-LXA4 from AA by acetylated COX2/5-LOX have been suggested as good strategies to reduce clinical signs in IBD ([@B50]; [@B33]). A recent report has also found that commercial RvE1 inhibits the oncoprotein c-Myc expression, overexpressed in a large variety of human cancers, and also in CAC model, which causes more tumor aggression and poor clinical outcomes ([@B59]; [@B12]) in normal human colon epithelial cells stimulated with TNFα and also in HCT116 human colon cells ([@B88]). Another recent study has pointed out that chemotherapy generates tumor cell debris, which stimulates tumorigenesis by the release of pro-inflammatory cytokines by macrophages, and that commercial RvE1, RvD1, and RvD2 can turn macrophages from pro-inflammatory/tumorigenic to a phagocytic phenotype, causing clearance of tumor cell debris and then preventing tumor recurrence ([@B80]). In colorectal adenoma recurrence, a randomized trial of aspirin did not found association between plasma levels of LXA4 and RvD1 and the risk of adenoma recurrence despite their previously mentioned anti-inflammatory and pro-resolving actions ([@B27]).

Although a large number of studies correlate the effect of EPA in pro-inflammatory mediator synthesis *via* COX-2 inhibition, it must be said that there is a lack of studies about the situation of SPMs in CRC despite the reported deficiency in one of the enzymes with a strong participation on its production, 15-LOX-1, as the largest contributor to the CRC ([@B76]; [@B77]).

Effect of ω3-PUFAs on Inflammation-Based Cancers of the Upper Gastrointestinal Tract {#s5}
====================================================================================

Gastroesophageal reflux disease (GERD) is a chronic disease caused by the reflux into the esophagus of acid, bile salts, and other noxious agents contained in gastric juice, which induces an inflammatory response and damage of the esophageal epithelium. Complications of reflux esophagitis include the development of ulcers and structures or Barrett's esophagus (BE), which is defined by the replacement of the normal squamous epithelium by an intestinal type metaplastic epithelium, which is a preneoplastic condition predisposing to esophageal adenocarcinoma ([@B79]). The effect of PUFAs has been evaluated in esophagitis, Barrett's metaplasia, and established adenocarcinoma. Thus, in an experimental model of reflux esophagitis in rats, intraperitoneal administration of a 10% ω3-fish oil-based lipid emulsion significantly decreased esophageal damage and inflammation, whereas administration of a 10% ω6-soybean oil-based lipid emulsion increased the damage ([@B89]). This model is associated with an increased expression of myeloid differentiation primary response gene 88 (MyD88), the proinflammatory cytokines IL-6, IL-8, and IL-1β, and oxidative stress. Interestingly, the authors found the lowest levels of proinflammatory mediators in the ω3-PUFAs-treated animals, whereas the ω6-PUFAs group showed the highest. Both ω3 and ω6-PUFAs reduced the levels of malondialdehyde, a marker of LPO, but the decrease was more pronounced in the ω3-PUFA group, which could be due to an increase in SOD expression, an effect that was exclusive of ω3-PUFAs treatment. A community-based study reported an inverse association between the intake of ω3-fatty acids and the risk of BE, where those who consumed the highest amount were at less than half the risk of developing BE and three times lower the risk to have a long segment BE than those who consumed the lowest amount ([@B45]). In a human intervention study, dietary supplementation with 1.5 g/day unesterified EPA for 6 months in patients with BE significantly changed ω3-fatty acid concentrations in Barrett's mucosa and reduced COX-2 protein expression, although without repercussion on PGE2 levels and cellular proliferation ([@B53]). PUFAs also might have a role as adjuvant therapy in established esophageal adenocarcinoma since ω3-PUFAs EPA and DHA have shown anti-proliferative effects on esophageal adenocarcinoma cell lines ([@B25]). A phase II clinical trial in patients with advanced esophago-gastric adenocarcinoma receiving palliative platinum-based chemotherapy showed that the addition of an intravenous infusion of omega ω3-PUFAs as a 10% fish oil lipid emulsion once weekly reduced chemotherapy-related toxicity and improved radiological response ([@B26]) ([**Table 1**](#T1){ref-type="table"}, [**Figure 1**](#f1){ref-type="fig"}).

In the stomach, *H. pylori* infection is the main risk factor for both gastritis and gastric carcinoma. It is considered to be the initiator of a chronic inflammatory response that contributes to the development of gastric cancer ([@B62]). There is some evidence suggesting a protective effect for ω3-PUFAs against *H. pylori*-associated gastric carcinogenesis. Recent studies have reported that ω3-PUFAs could have antimicrobial activity against *H. pylori*, inhibiting its growth and colonization of gastric mucosa ([@B20]). Fat-1 transgenic mice overexpress n-3 desaturase, leading to abundant ω3-PUFAS with reduced levels of ω6-fatty acids in their organ and tissues without a dietary ω3 supply. Using a model of gastric tumorigenesis induced by *H. pylori* infection and high salt diet, Han et al. found that Fat-1 mice were protected against *H. pylori*-induced inflammation, chronic atrophic gastritis, and the development of gastric carcinoma compared to wild type mice ([@B34]). Moreover, the expression of inflammatory and angiogenic growth factors such as COX-2, IL-1β, VEGF, and PDGF was significantly decreased in Fat-1 mice. The authors estimated dietary intake of ω3-PUFAs of more than 0.5 g/60 kg to achieve lipid profile similar to that of Fat-1 mice. This study provides relevant preclinical evidence of the effect of ω3-PUFAs on *H. pylori*-induced gastric carcinogenesis and the dose necessary to achieve it ([**Table 1**](#T1){ref-type="table"}, [**Figure 1**](#f1){ref-type="fig"}).

Conclusions and Potential Future Developments {#s6}
=============================================

Although research on the role of ω3-PUFAs and SPMs on inflammation and cancer is rising continuously and seems to indicate a general positive effect of supplementation on colorectal, esophageal, and gastric cancers, larger efforts should be made to perform high-quality randomized control trials to establish their mechanisms of action, the best timing on supplementation, dosage, source of these products, way of extraction, preparation and quantification, and well-suited nutritional questionnaires to obtain the biggest efficacy, which will allow us to set the use of these compounds in clinical guidelines for cancer prevention.
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